IOL Chemicals and Pharmaceuticals Limited — Investor Meet, 18-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

IOLCP's Q3 FY26 revenue rose 10.9% to INR 580 Cr, with EBITDA up 22.8% to INR 62.6 Cr and 10.7% margin. Declared 50% interim dividend; noted an INR 11.2 Cr exceptional item for new labor law provisions. Management highlighted robust diversified business performance and increasing non-ibuprofen API traction, enhancing margin quality. Ibuprofen and chemical plants maintain high utilization. For FY27, the company anticipates 10-15% top-line growth, targeting regulated markets and greater non-ibuprofen API share. Q4 projections include INR 600 Cr revenue and improved EBITDA margins. Confident in strategic direction for sustained growth.